Article Text
Research ethics
Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics Report
Abstract
In September this year the Nuffield Council on Bioethics held a meeting to disclose and discuss the main findings of their newly published report on the ethical issues associated with developments in pharmacogenetics research. The basics of pharmacogenetics science is briefly outlined, and then the extent to which the report was successful in addressing (or at least highlighting) the attendant social, ethical, and policy implications of pharmacogenetics research is evaluated.
- ADR, adverse drug reaction
- DNA banking
- pharmacogenetics
- consent
- hype
Statistics from Altmetric.com
Footnotes
-
The Wellcome Trust sponsored my research in this area.
-
Competing interests: none declared
Read the full text or download the PDF:
Other content recommended for you
- Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study
- Adverse drug reactions of non-statin antihyperlipidaemic drugs in China from 1989 to 2019: a national database analysis
- Adverse drug reactions of statin therapy in China from 1989 to 2019: a national database analysis
- Influence of metabolic profiles on the safety of drug therapy in routine care in Germany: protocol of the cohort study EMPAR
- Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
- Safety of ceftriaxone in paediatrics: a systematic review
- Adverse drug reactions in childhood: a review of prospective studies and safety alerts
- OHP-045 Incidence and risk factors of adverse drug reactions in the general population observed through an active pharmacovigilance project
- Study protocol for a multicentre, open-label, single-arm phase I/II trial to evaluate the safety and efficacy of ripasudil 0.4% eye drops for retinopathy of prematurity
- Clinical and economic impact of adverse drug reactions in hospitalised patients: prospective matched nested case–control study in Ethiopia